By Connor Hart
Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading.
Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading.
Instacart parent Maplebear was selected for inclusion in the S&P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&P SmallCap 600 from the S&P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 07, 2025 18:36 ET (23:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.